Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Recurrence 1Anemia 1

Interventions

Rituximab 17Cyclophosphamide 8zanubrutinib 7Bendamustine Hydrochloride 7obinutuzumab 6Lenalidomide 6venetoclax 5blinatumomab 5acalabrutinib 5Vincristine 5fludarabine 4Prednisone 4Methotrexate 4Doxorubicin 4Cytarabine 4Brentuximab Vedotin 4ibrutinib 3Specimen Handling 3Dexamethasone 3Crizotinib 3tisagenlecleucel 2tafasitamab 2polatuzumab vedotin 2pirtobrutinib 2pegaspargase 2idelalisib 2duvelisib 2axicabtagene ciloleucel 2avapritinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × ibrutinib × Lymphoid × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03734016 2025-03-30

ALPINE

BeiGene

Phase 3 Completed
652 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03053440 2024-10-26

ASPEN

BeiGene

Phase 3 Completed
201 enrolled 19 charts 1 FDA
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡